Is De-escalated Bisphosphonates Therapy a Suitable Alternative to Standard Dosing in Malignant Tumor Patients With Bone Metastases: A Systematic Review and Meta-Analysis

Background: Previous studies have preliminarily identified the non-inferior efficacy for reducing skeletal-related event (SRE) rates between de-escalated (Q12w) and standard (Q3-4w) bone-targeting agents therapy in malignant tumor patients with bone metastases. In this study, we aim to make further...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Qiuhua, Men, Peng, Liu, Zhiyong, Zhai, Suodi, Jiang, Mingyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702312/
https://www.ncbi.nlm.nih.gov/pubmed/31475116
http://dx.doi.org/10.3389/fonc.2019.00774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702312/
https://www.ncbi.nlm.nih.gov/pubmed/31475116
http://dx.doi.org/10.3389/fonc.2019.00774

Ejemplares similares